echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Three groups of countries to adopt the implementation of the program and rules at the end of July, the winning rules change or not change?

    Three groups of countries to adopt the implementation of the program and rules at the end of July, the winning rules change or not change?

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide Read: The do not select in the volume purchase is secondary, running up is more important!---- Recently, the network's conference on the third batch of national collection was held in ShanghaiIt is reported that the third batch of volume procurement rules are basically finalized, is expected to open on August 18, the end of July will be issued implementation plans and rulesWith regard to the selection rules, the rules for the second batch of countries are basically the same, using a 1.8-fold fuse mechanism and a 50 per cent reduction in prices(What is the final content, of course, subject to the official announcement)On July 21, Shanghai Sunshine Pharmaceutical Procurement Network issued a "Notice on the collection of basic information related to some drugs", introducing 86 standard drug collection related information"Notice" indicates that the information collection work is only used for related work exploration and analysis research, not as a basis for the declaration of drug centralized procurement enterprises, the specific declaration of enterprise qualifications and the declaration of varieties of eligibility to the procurement documentsAccording to the network's public data, 86 product regulations in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 56 billion yuan, involving a total of 300 pharmaceutical companiesIn the third round of collection varieties, China Biopharmaceuticalled led by 9 over-rated varieties; Qilu Pharmaceuticals, Haussen Pharmaceuticals, Hengrui Pharmaceuticals, Stone Pharmaceutical Group and other 4 enterprises involved in the number of varieties reached 6; Huahai Pharmaceuticals and a group of competitors hold 3 overrated varieties involved, it is not obvious"Winning rules: if "the third batch and the second batch of winning rules are basically the same" first, this to a certain extent means that the reform mature stereotypes, at least in the third batch of decision-making on the second batch of winning and losing (pattern, effect) is more recognized; Strategically, it is long overdue to give up the illusion that the overall promotion of centralized procurement is a set-up; third, it should look back at the similarities and differences of the first three batches of tape procurement (rules, effects): the first batch is a pilot, is local competition, the rules and the second batch of differences are more normal; For example: We in the second batch of drug country picksaw Zhengda Qing refused to renew the contract of Entikawe, see Qilu albumin yew alcohol selection, etc, which in fact reflects the enterprise's own choiceOn the one hand, the supply market competition is more diversified, on the other hand, it also allows enterprises to have trade-offsLooking at the future situation of drug-belt procurement, we need to think: First, the pattern of tape procurement accounted for the full amount of collection1, the focus is not only in generic drugs, chemical drugs, may affect biological-like drugs, traditional Chinese medicine, etc, until including biological products, Chinese medicine, etc; Second, in addition to the volume of procurement, there are also which collection tools (such as GPO, price limit hanging network, direct hanging network, record procurement innovation, etc.), and the amount of procurement rules after the moderate training how to remove some excessive administrative (if any) problemsIf the third batch of winning rules and the second batch are close to the same, perhaps revealed to move forward in this direction: that is, respect for the "quantitative price linkage" principle under the existing market competition performance, continue to use the form of volume procurement to find new, fast-landing trading prices, stirring new drug reformEnterprise transformation: either the use of the drug "group magic dance" or their own lonely from the corporate point of viewMainly "1.8 times the fuse mechanism and 50% price reduction", respectively, to limit the price range and price reduction rangeLet's first look at the rationality: first, the third batch is the expansion of varieties, the number is still limited (dozens), and the standard conditions do not seem to be reduced (several over-reviews), next to the second batch in doing, the supply of competition pattern and demand efficiency purposes are close to the same, the principle is similar and reasonableIt's not surprising if the next fourth and fifth batch is still at that paceSecondly, the volume procurement in the chemical generic sourcing centralized procurement, in the centralized procurement of all drugs has been accounted for, will account for the proportion in a certain period of time by the impact of technical restrictions, each band purchase for each shortlisted variety only forced a certain proportion of the agreed procurement volumeIt is not surprising if a business refuses to bid and instead competes for the remaining market and off-court marketAt present, the volume of procurement and admission between the hospital is drawing more equal signs, the defeated drugs in the collection of stable prices outside the double-loneliness"On July 20, Shaanxi Province released the "Shanxi Province Public Resources Trading Center drug sunshine network dynamic adjustment implementation plan", will focus on the hanging network product prices dynamic adjustment, after the adjustment, dynamic adjustment work will enter the normalIt is proposed to explore the establishment of a price-limiting network system for low-cost drugs based on independent quotations, to carry out volume procurement or multi-participation price negotiations on high-value and heavy-use drugs, and to encourage private medical institutions that enjoy the medical insurance reimbursement policy to participate in the purchase of drugs in the sunOn July 20, Jiangxi Province issued a notice announcing the standard of payment for health insurance for some generic drugs (including biosimilars) in 18 countries"Regarding the out-of-hospital market, that is, the market of prescription outflow, in the comprehensive medical reform, we should also jump out of the "quantitative price-linked" collection principle, pay attention to the reform of the gradual unified payment standard of medical insuranceAt present, on the one hand is the chain of retail pharmacies, e-commerce drugs, DTP pharmacy volume and share growth is dazzling, on the other hand, more and more To patients' sales terminals and health insurance payment cooperation, affected by the health insurance payment policyComprehensive medical reform adheres to the people's interests as the center, the process and results of prescription outflow will inevitably reflect the effectiveness of drug price reformAmong them, we believe that: the volume of procurement of chemical generics, public hospitals clinical guarantee dispensing is the specific work on the two breakthroughs, these two work to maintain the rhythm, efficiency, do not worry about other centralized procurement methods, the efficiency of other medical and health institutions is still in a backward position for the time being, may lead to the entire pharmaceutical market efficiency reform small step run, and may achieve the pharmaceutical industry supply side production and research structure upgrade of the "cage for birds." At the end of the text, the meeting is still held in Shanghai, the lunar calendar 8.18 is the Qiantang River tideThe CHS-DRG sub-group scheme was launched at 6.18Overall, the feeling that Health Care-led drug price reform is more and more confident In the future, deepening reforms will certainly touch more interests and inspire skepticism But with the specific measures represented by the volume of procurement adhere to the people's interests as the center, adhere to the rules of fairness and transparency, will be indomitable, resilient Promising pharmaceutical companies should run around avoiding cattle noses, even if they don't run with the noses of cattle The non-selection in the band purchase is secondary, running is more important
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.